Skip to content

Starting ART two weeks after TB treatment reduces death risk by one-third in people with HIV

Once-daily extended-release nevirapine works as well as twice-daily formulation

Experimental integrase inhibitor GSK-572 shows continued promise

Early treatment for infants cheaper than delaying treatment, CHER study shows

Ugandan study shows why human rights are central to HIV prevention with African men who have sex with men

Rilpivirine (TMC278) matches efavirenz in phase 3 studies, with fewer side-effects

Hepatitis C epidemic in HIV-positive gay men in Netherlands seems to have levelled off

Incentives and phone follow-up could improve healthy behaviour by young people: more research needed

The future of AIDS activism: looking for sustained energy and new tactics 10 years after Durban